Evan J. Anderson
A5079489250- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- COVID-19 Clinical Research Studies
- Pneumonia and Respiratory Infections
- Viral gastroenteritis research and epidemiology
- Vaccine Coverage and Hesitancy
- Animal Virus Infections Studies
- Kawasaki Disease and Coronary Complications
- SARS-CoV-2 detection and testing
- Neonatal Respiratory Health Research
- Congenital Diaphragmatic Hernia Studies
- COVID-19 Impact on Reproduction
- Viral Infections and Immunology Research
- COVID-19 epidemiological studies
- Long-Term Effects of COVID-19
- Hepatitis Viruses Studies and Epidemiology
- COVID-19 and healthcare impacts
- Emergency and Acute Care Studies
- Nosocomial Infections in ICU
- Sepsis Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Mosquito-borne diseases and control
- Streptococcal Infections and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
Moderna Therapeutics (United States)
2023-2025
Emory University
2016-2025
Children's Healthcare of Atlanta
2014-2025
Children's Center
2017-2025
Veterans Health Administration
2015-2024
Georgia Department of Public Health
2015-2024
HOPE Clinic
2020-2024
Sandia National Laboratories
2021-2024
Pfizer (United States)
2024
Yale University
2023
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. We conducted phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 55 years age, who received two vaccinations, 28 days apart, with dose 25 μg, 100 or 250 μg. There were 15 participants each group. After...
Community-acquired pneumonia is a leading infectious cause of hospitalization and death among U.S. adults. Incidence estimates confirmed radiographically with the use current laboratory diagnostic tests are needed.
Since SARS-CoV-2, the novel coronavirus that causes disease 2019 (COVID-19), was first detected in December (1), approximately 1.3 million cases have been reported worldwide (2), including 330,000 United States (3). To conduct population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations States, COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) created using existing infrastructure of Influenza (FluSurv-NET) (4) and Respiratory Syncytial Virus...
Incidence estimates of hospitalizations for community-acquired pneumonia among children in the United States that are based on prospective data collection limited. Updated has been confirmed radiographically and with use current laboratory diagnostic tests needed.We conducted active population-based surveillance requiring hospitalization younger than 18 years age three hospitals Memphis, Nashville, Salt Lake City. We excluded recent or severe immunosuppression. Blood respiratory specimens...
Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences illness and death from disease 2019 (Covid-19) have been associated age. We conducted a phase 1, dose-escalation, open-label trial messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein (S-2P) healthy adults. The was expanded include 40 adults, who were stratified...
Coronavirus disease 2019 (COVID-19) represents a global crisis, yet major knowledge gaps remain about human immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We analyzed immune responses in 76 COVID-19 patients and 69 healthy individuals from Hong Kong Atlanta, Georgia, United States. In the peripheral blood mononuclear cells (PBMCs) of patients, we observed reduced expression leukocyte antigen class DR (HLA-DR) proinflammatory cytokines by myeloid as well impaired...
Abstract Background Currently, the United States has largest number of reported coronavirus disease 2019 (COVID-19) cases and deaths globally. Using a geographically diverse surveillance network, we describe risk factors for severe outcomes among adults hospitalized with COVID-19. Methods We analyzed data from 2491 laboratory-confirmed COVID-19 between 1 March–2 May 2020, as identified through Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, which comprises 154...
At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy preventing coronavirus disease 2019 (Covid-19). After emergency use of was authorized, protocol amended to include an open-label phase. Final analyses and safety data from blinded trial are reported.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, angiotensin-converting enzyme (ACE2)–competing antibodies elicited by messenger RNA (mRNA) vaccine mRNA-1273 7 months. Cross-reactive...
SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide pandemic, and there pressing need to understand development, specificity, neutralizing potency of humoral immune responses during acute infection. We report cross-sectional study antibody receptor-binding domain (RBD) spike protein neutralization activity in cohort 44 hospitalized COVID-19 patients. RBD-specific IgG are detectable all patients 6 days after PCR confirmation. Isotype switching occurs rapidly,...
COVID-NET conducts population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in 99 counties † 14 states (California, Connecticut, Colorado, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, York, Ohio, Oregon, Tennessee, and Utah), representing all 10 U.S. Department of Health Human Services regions (2,3).Laboratory-confirmed COVID-19associated among residents a predefined catchment area who had positive SARS-CoV-2 molecular test during...
Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 patients longitudinally up 8 months and find durable broad-based immune responses. SARS-CoV-2 spike binding neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting generation longer-lived plasma cells. infection also boosts antibody titers SARS-CoV-1 common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well...
Pregnant women might be at increased risk for severe coronavirus disease 2019 (COVID-19) (1,2). The COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) (3) collects data on hospitalized pregnant with laboratory-confirmed SARS-CoV-2, the virus that causes COVID-19; to date, such have been limited. During March 1-August 22, 2020, approximately one in four aged 15-49 years COVID-19 was pregnant. Among 598 COVID-19, 54.5% were asymptomatic admission. 272 who symptomatic hospital...
Abstract Background Data on risk factors for coronavirus disease 2019 (COVID-19)–associated hospitalization are needed to guide prevention efforts and clinical care. We sought identify independently associated with COVID-19–associated hospitalizations. Methods Community-dwelling adults (aged ≥18 years) in the United States hospitalized laboratory-confirmed COVID-19 during 1 March–23 June 2020 were identified from COVID-19–Associated Hospitalization Surveillance Network (COVID-NET), a...
hospital admissions are subject to lag.
Abstract Background The severity of the 2017–2018 influenza season in United States was high, with A(H3N2) viruses predominating. Here, we report vaccine effectiveness (VE) and estimate number vaccine-prevented influenza-associated illnesses, medical visits, hospitalizations, deaths for season. Methods We used national age-specific estimates coverage disease burden. estimated VE against medically attended reverse-transcription polymerase chain reaction–confirmed virus infection ambulatory...
Context Evolution of polymerase chain reaction testing for infectious pathogens has occurred concurrent with a focus on value-based medicine. Objective To determine if implementation the FilmArray rapid respiratory panel (BioFire Diagnostics, Salt Lake City, Utah) (hereafter RRP), shorter time to test result and expanded panel, results in different outcomes children admitted hospital an acute tract illness. Design Patient were compared before RRP (November 1, 2011, January 31, 2012) versus...
OBJECTIVES Describe population-based rates and risk factors for pediatric severe coronavirus disease 2019 (COVID-19) (ie, ICU admission, invasive mechanical ventilation, or death). METHODS During March 2020 to May 2021, the COVID-19–Associated Hospitalization Surveillance Network identified 3106 children hospitalized with laboratory-confirmed acute respiratory syndrome 2 infection in 14 states. Among 2293 primarily admitted COVID-19, multivariable generalized estimating equations generated...
<h3>Importance</h3> Racial and ethnic minority groups are disproportionately affected by COVID-19. <h3>Objectives</h3> To evaluate whether rates of severe COVID-19, defined as hospitalization, intensive care unit (ICU) admission, or in-hospital death, higher among racial compared with non-Hispanic White persons. <h3>Design, Setting, Participants</h3> This cross-sectional study included 99 counties within 14 US states participating in the COVID-19–Associated Hospitalization Surveillance...
Recent trials suggest procalcitonin-based guidelines can reduce antibiotic use for respiratory infections. However, the accuracy of procalcitonin to discriminate between viral and bacterial pneumonia requires further dissection. We evaluated association serum concentration at hospital admission with pathogens detected in a multicenter prospective surveillance study adults hospitalized community-acquired pneumonia. Systematic pathogen testing included cultures, serology, urine antigen tests,...
The first U.S. case of COVID-19 attributed to the Omicron variant SARS-CoV-2 (the virus that causes COVID-19) was reported on December 1, 2021 (1), and by week ending 25, 2021, predominant circulating in United States.* Although COVID-19-associated hospitalizations are more frequent among adults,† can lead severe outcomes children adolescents (2). This report analyzes data from Coronavirus Disease 19-Associated Hospitalization Surveillance Network (COVID-NET)§ describe (aged 0-11 years)...